These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 25407369)
1. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? Lucas MC; Tan SL Future Med Chem; 2014; 6(16):1811-27. PubMed ID: 25407369 [TBL] [Abstract][Full Text] [Related]
2. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081 [TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216 [TBL] [Abstract][Full Text] [Related]
4. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104 [TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. Norman P Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review. Kaur M; Singh M; Silakari O Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087 [TBL] [Abstract][Full Text] [Related]
7. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132 [TBL] [Abstract][Full Text] [Related]
8. Rational design of highly selective spleen tyrosine kinase inhibitors. Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054 [TBL] [Abstract][Full Text] [Related]
9. Properties of FDA-approved small molecule protein kinase inhibitors. Roskoski R Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063 [TBL] [Abstract][Full Text] [Related]
10. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514 [TBL] [Abstract][Full Text] [Related]
11. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase. Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137 [TBL] [Abstract][Full Text] [Related]
12. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013. Thorarensen A; Kaila N Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321 [TBL] [Abstract][Full Text] [Related]
13. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola. Moore WJ; Richard D; Thorarensen A Expert Opin Ther Pat; 2010 Dec; 20(12):1703-22. PubMed ID: 21073366 [TBL] [Abstract][Full Text] [Related]
14. Novel small molecule therapeutics in rheumatoid arthritis. Kelly V; Genovese M Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340 [TBL] [Abstract][Full Text] [Related]
15. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. Zhao H; Huang D; Caflisch A ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951 [TBL] [Abstract][Full Text] [Related]
16. Identification of type-II inhibitors using kinase structures. Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374 [TBL] [Abstract][Full Text] [Related]
17. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013). Norman P Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480 [TBL] [Abstract][Full Text] [Related]
18. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873 [TBL] [Abstract][Full Text] [Related]
19. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Dymock BW; See CS Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873 [TBL] [Abstract][Full Text] [Related]
20. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. Baladi T; Abet V; Piguel S Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]